Octalia Technologies is a fully independent company specialized in pharmaceutical sciences writing which supports your R&D teams throughout your therapeutic research programs.

Octalia Technologies was founded in 2006 by highly experienced scientists who have collected an extended knowledge while working for well-known pharmaceutical groups. Always on the go to discover new formulations and drug delivery concepts, they leverage over 30 years of experience in all stages of the drug development process: formulation, analysis, pharmaceutical drug development and applied research that integrated the industrial scale-up needs.

In 2016, Octalia Technologies became the first and unique GLP organization dedicated to formulation and analysis and has been involved in a dozen of GLP multisite studies as test site (Spain, Germany, UK and USA): over 40 batches of supplies have been prepared in two years for non-clinical testing.

Building on this experience, our commitment is now exclusively focused on scientific writing. We have delved into the intricacies of formulation, tested hypotheses, and refined our knowledge. This expertise is now our major asset in writing pharmaceutical CMC dossiers. Every word, every sentence we write is the result of meticulous analysis. We understand the importance of details and their impact on the quality of MAA dossiers. Our transition from laboratory to writing has been seamless. Our ability to communicate effectively is the essential link between science and regulatory authorities.

We are agile and responsive; we recognize the urgency of deadlines and commit to delivering quality work within the allotted time.